Skip to Content

A011801: The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (Location: Yankton)

Principal Investigator(s)
John Lee, MD

Clinical Trial Categories

  • Breast Cancer
Gynecology Breast Coordinators at 605-322-7536
How to Participate

Clinical Trial Details >>


  • Avera Cancer Institute at Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.